Polymorphisms of the Tissue Factor Pathway Inhibitor (TFPI) Gene in Patients With Acute Coronary Syndromes and in Healthy Subjects
- 1 April 1999
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 19 (4) , 862-869
- https://doi.org/10.1161/01.atv.19.4.862
Abstract
—Mutations of the gene encoding tissue factor pathway inhibitor (TFPI), an inhibitor of TF-induced activation of the coagulation cascade, were screened for in 130 patients and 142 healthy controls to determine whether these variants contribute to acute coronary syndromes or modify plasma TFPI levels. The following 3 new polymorphisms were identified: 384T→C in exon IV, which does not change the corresponding amino acid (tyrosine 57); −33C→T in intron 7 (the T/T, C/T, and C/C genotypes were found in ≈50%, 40%, and 10% of subjects in both groups); and 874G→A in exon IX (GTG→ATG), which predicts a valine to methionine change (V264M) in the carboxy-terminus tail of TFPI. The V264M polymorphism was found in 9.2% of the cases and 4.9% of the controls; the associated odds ratio (OR) for acute coronary syndromes was 2.0 (95% confidence interval [CI], 0.7 to 5.1). The OR increased to 3.6 (95% CI, 0.8 to 15.7) and 3.2 (95% CI, 0.9 to 11.8) in nonsmokers and patients without other risk factors, respectively. The possible link between the V264M polymorphism and coronary heart disease was checked in a large case-control study of myocardial infarction (Etude Cas-Témoins de l’Infarctus du Myocarde [the ECTIM Study]). The results showed no link between the V264M polymorphism and coronary syndromes. Interestingly, however, 5 patients heterozygous for the V264M polymorphism had significantly lower plasma TFPI levels than did 13 patients with the most common genotype. Although our present results do not support an association between TFPI polymorphisms and acute coronary syndromes, the possibility that 1 of them, especially the exon IX polymorphism, is associated with subtypes of myocardial infarction or to evolutive particularities that were not assessed in this study, cannot be excluded and is currently being evaluated.Keywords
This publication has 26 references indexed in Scilit:
- The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo.Journal of Clinical Investigation, 1995
- Revised DNA sequence of exon 1 and 5′ flanking region of the human tissue factor pathway inhibitor geneThrombosis Research, 1993
- Psoralen-modified oligonucleotide primers improve detection of mutations by denaturing gradient gel electrophoresis and provide an alternative to GC-clampingHuman Molecular Genetics, 1993
- Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitorThrombosis Research, 1993
- Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarctionNature, 1992
- The Pathogenesis of Coronary Artery Disease and the Acute Coronary SyndromesNew England Journal of Medicine, 1992
- Chromogenic substrate assay of extrinsic pathway inhibitor (EPI)Blood Coagulation & Fibrinolysis, 1991
- Intron-exon organization of the human gene coding for the lipoprotein-associated coagulation inhibitor: the factor Xa dependent inhibitor of the extrinsic pathway of coagulationBiochemistry, 1991
- The world health organization monica project (monitoring trends and determinants in cardiovascular disease): A major international collaborationJournal of Clinical Epidemiology, 1988
- [30] Computational simulation of DNA melting and its application to denaturing gradient gel electrophoresisPublished by Elsevier ,1987